Royal Bank of Canada’s PharmaCyte Biotech PMCB Stock Holding History

Royal Bank of Canada’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-98	Closed	–	–	7146
2024 Q4	$0	Sell	98 -2	-2%	-$3	﹤0.01%	7161
2024 Q3	$0	Sell	100 -161	-62%	-$300	﹤0.01%	7293
2024 Q2	$0	Buy	261 +105	+67%	+$226	﹤0.01%	7424
2024 Q1	$0	Sell	156 -109	-41%	-$236	﹤0.01%	7457
2023 Q4	$0	Buy	265 +167	+170%	+$362	﹤0.01%	7472
2023 Q3	$0	Hold	98	–	–	﹤0.01%	7448
2023 Q2	$0	Hold	98	–	–	﹤0.01%	7555
2023 Q1	$0	Hold	98	–	–	﹤0.01%	7381
2022 Q4	$0	Sell	98 -53	-35%	-$152	﹤0.01%	7600
2022 Q3	$0	Buy	151 +53	+54%	+$134	﹤0.01%	7755
2022 Q2	$0	Hold	98	–	–	﹤0.01%	7634
2022 Q1	$0	Hold	98	–	–	﹤0.01%	7945
2021 Q4	$0	Sell	98 -564	-85%	-$1.55K	﹤0.01%	7837
2021 Q3	$2K	Buy	+662	New	+$2.33K	﹤0.01%	7353

Other funds holding PMCB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Royal Bank of Canada's PMCB Position: Q1 2025 in Review

Royal Bank of Canada sold out of PharmaCyte Biotech (PMCB) in Q1 2025, closing a stake of 98 shares.

Royal Bank of Canada first reported a position in PMCB in Q3 2021 and held it in 14 quarters. The position peaked at $2K in Q3 2021. 24 funds tracked by Wall St. Rank hold PMCB as of Q1 2025.

Royal Bank of Canada reported no remaining PharmaCyte Biotech position as of Q1 2025 after selling out during the quarter.
Royal Bank of Canada sold 98 PharmaCyte Biotech shares in Q1 2025.
Royal Bank of Canada first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 14 quarters.
Royal Bank of Canada's PharmaCyte Biotech position peaked at $2K in Q3 2021.
24 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2025.

Based on Royal Bank of Canada's 13F filing for Q1 2025, filed 15 May 2025.